VICTORIA, BC, April 20,
2023 /CNW/ - Eupraxia Pharmaceuticals
Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a Phase 2
clinical-stage biotechnology company with an innovative drug
delivery technology platform, today announced that it will
deliver a corporate presentation at the 2023 Bloom Burton & Co.
Healthcare Investor Conference in Toronto.
Eupraxia CEO Dr. James
Helliwell will present on Tuesday,
April 25th, 2023, at 10:30 a.m.
ET at the Metro Toronto Convention Centre, and will
participate in investor meetings at the conference on April 25th and 26th.
Interested parties can access the presentation through the
About Eupraxia Pharmaceuticals
Eupraxia is a clinical-stage biotechnology company focused on
the development of locally delivered, extended-release alternatives
to currently approved drugs. Each of Eupraxia's product candidates
has the potential to address therapeutic areas with high unmet
medical need and strives to provide improved patient benefit by
delivering targeted, long-lasting activity with fewer side
Eupraxia's lead product candidate, EP-104, is currently in Phase
2 development for the treatment of pain due to osteoarthritis of
the knee. The EP-104 platform has expanded into gastrointestinal
disease with the launch of a Phase 1b/2a program to treat eosinophilic esophagitis.
Eupraxia is also developing a pipeline of later- and earlier-stage
long-acting formulations. Potential pipeline indications include
candidates for both other inflammatory joint indications and
oncology, each designed to improve on the activity and tolerability
of currently approved drugs. For further details about Eupraxia,
please visit the Company's website at: www.eupraxiapharma.com.
SOURCE Eupraxia Pharmaceuticals Inc.